ABIOMED INC: directors' dealings · United States · SEC (Form 4)

About ABIOMED INC

ABIOMED INC. was historically a U.S. specialist in circulatory support and cardiac assist technologies and is now part of Johnson & Johnson MedTech. Prior to its acquisition, the company was listed on the U.S. NASDAQ market under the ticker ABMD and was best known for its Impella platform, a family of minimally invasive percutaneous heart pumps designed to temporarily unload the heart, maintain blood flow, and support patient recovery. Abiomed was founded in 1981 in Danvers, Massachusetts, with an original ambition to develop the world’s first artificial heart. Over time, its strategic focus evolved toward “native heart recovery,” meaning helping the patient’s own heart recover rather than permanently replacing cardiac function. The core product portfolio centered on the Impella family, including Impella CP, Impella 5.5, and Impella RP, along with SmartAssist-enabled versions and related clinical support offerings. These devices are used in high-risk PCI and cardiogenic shock settings, which positions ABIOMED in a highly specialized, clinically driven medtech niche. That niche is attractive from a competitive standpoint because it combines regulatory barriers, procedure-level expertise, and recurring clinician training and support. Abiomed also emphasized on-site, on-call, and online clinical services, which reinforced customer adoption and differentiated the platform from more commoditized medical-device offerings. Geographically, ABIOMED was anchored in the United States, with headquarters in Danvers, Massachusetts, and a steadily expanding international footprint, including Europe and Japan. The company’s history was marked by sustained innovation, a meaningful patent base, and a strong clinical-development pipeline. For investors, the most important recent milestone is the acquisition by Johnson & Johnson, announced in 2022 and completed on December 22, 2022. Following closing, Abiomed ceased to exist as an independent publicly traded company, and the business now operates as a standalone platform within Johnson & Johnson MedTech. From an equity-investor perspective, ABIOMED is therefore best understood as a former U.S. growth medtech company whose value proposition rested on breakthrough cardiovascular technology, strong clinical adoption, and intellectual-property depth. Although ABMD is no longer an active listed stock, Abiomed’s operating legacy remains strategically important inside Johnson & Johnson’s cardiovascular portfolio in the United States and internationally.